Last reviewed · How we verify
Arm A: ABC+3TC+NNRTI
This combination inhibits HIV reverse transcriptase through two nucleoside analogs (ABC and 3TC) and one non-nucleoside reverse transcriptase inhibitor (NNRTI), blocking viral replication.
This combination inhibits HIV reverse transcriptase through two nucleoside analogs (ABC and 3TC) and one non-nucleoside reverse transcriptase inhibitor (NNRTI), blocking viral replication. Used for HIV-1 infection.
At a glance
| Generic name | Arm A: ABC+3TC+NNRTI |
|---|---|
| Also known as | ABC: abacavir: Ziagen, 3TC: lamivudine: Epivir, ABC+3TC co-formulated: Kivexa, NVP: nevirapine, Viramune, EFV: efavirenz, Sustiva |
| Sponsor | Medical Research Council |
| Drug class | Antiretroviral combination therapy (nucleoside reverse transcriptase inhibitors + non-nucleoside reverse transcriptase inhibitor) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
ABC (abacavir) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors that compete with natural nucleotides and cause chain termination during viral DNA synthesis. The NNRTI component binds directly to reverse transcriptase and blocks its catalytic activity. Together, these three agents suppress HIV replication through complementary mechanisms targeting the same enzyme.
Approved indications
- HIV-1 infection
Common side effects
- Hypersensitivity reaction (abacavir)
- Nausea
- Diarrhea
- Rash (NNRTI-related)
- Headache
- Hepatotoxicity
- Lactic acidosis
Key clinical trials
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen (PHASE3)
- Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arm A: ABC+3TC+NNRTI CI brief — competitive landscape report
- Arm A: ABC+3TC+NNRTI updates RSS · CI watch RSS
- Medical Research Council portfolio CI